Drug Trial Radar · NCT01918488
Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease
Last checked: Nov 19, 2026Latest source record: Oct 16, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
80
Planned (sponsor's estimate)
Start
Oct 2013
Primary completion
Dec 2014
Sponsor
- Lead sponsor
- University of Southern DenmarkAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Odense University Hospital; Region of Southern Denmark; The Ministry of Science, Technology and Innovation, Denmark; Danish Heart Foundation
- First posted
- Aug 7, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine whether a diuretic drug called amiloride is capable of increasing renal salt excretion and thereby decrease blood pressure in diabetic patients with kidney disease. Our hypothesis states that amiloride is capable of reducing blood pressure in these patients and thus decrease the cardiovascular risk associated with diabetic kidney disease.
Conditions
- Diabetic Nephropathies
- Hypertension
Interventions
Standardized salt dietDietary supplement
200 mmol NaCl per day given as three meals daily for 4 consecutive days.
AmilorideDrug
Amiloride tablet 20 mg two times daily (morning and afternoon) for two consecutive days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 24-hour urinary sodium excretion induced by amilorideTime frame: Change from baseline urinary sodium excretion at 24 hours after amiloride administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cardiovascular and Renal Research
Odense, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.